Monte Rosa Therapeutics (GLUE) Net Cash Flow Growth (3y) (2023 - 2026)
Monte Rosa Therapeutics (GLUE) Net Cash Flow Growth (3y) (2023 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
NCF Growth (3y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
- |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
89.97% |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
-13.44% |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
33.37% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Monte Rosa Therapeutics |
1.83 Bn |
1.15 Bn |
- |
127.58% |
| Date | Value |
|---|
| Mar 31, 2026 |
127.58% |
| Dec 31, 2025 |
-10.94% |
| Sep 30, 2025 |
152.08% |
| Jun 30, 2025 |
36.13% |
| Mar 31, 2025 |
11.16% |
| Dec 31, 2024 |
97.33% |
| Sep 30, 2024 |
18.91% |
| Jun 30, 2024 |
-63.64% |
| Mar 31, 2024 |
-30.48% |
| Dec 31, 2023 |
108.57% |
| Sep 30, 2023 |
-32.97% |
